Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pelareorep + oxaliplatin + irinotecan + leucovorin + fluorouracil + atezolizumab
- Development stage
- Unknown
- Lead developer
- Oncolytics Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
pelareorep + oxaliplatin + irinotecan + leucovorin + fluorouracil + atezolizumab is an investigational combination regimen consisting of the intravenously delivered oncolytic reovirus pelareorep, the modified FOLFIRINOX chemotherapy regimen (oxaliplatin, irinotecan, leucovorin, and fluorouracil), and the anti-PD-L1 monoclonal antibody atezolizumab. This combination is being evaluated as a first-line therapy for patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) in Cohort 5 of the Phase 1/2 GOBLET trial. Pelareorep selectively infects and lyses cancer cells, releasing viral double-stranded RNA that stimulates a pro-inflammatory response, increases T-cell infiltration, and upregulates PD-L1 expression. This immunologically "hot" tumor microenvironment is intended to synergize with atezolizumab, which blocks PD-L1 to restore T-cell-mediated anti-tumor activity, while the modified FOLFIRINOX regimen provides cytotoxic tumor debulking.
- Other names
- pelareorep + FOLFIRINOX + atezolizumabpelareorep + mFOLFIRINOX + atezolizumabpelareorep + modified FOLFIRINOX + atezolizumab
02
Targets
CD80 (T-lymphocyte activation antigen CD80)DNATOP1 (DNA Topoisomerase I)JAM-A (Junctional adhesion molecule A)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pelareorep + oxaliplatin + irinotecan + leucovorin + fluorouracil + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pelareorep + oxaliplatin + irinotecan + leucovorin + fluorouracil + atezolizumab.